RecruitingNCT06291324

WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment

Wearable Activity Tracker Devices and Cancer-Related Fatigue: A Clinical Utility Pilot Study For Patients Undergoing Anti-Cancer Treatment

Sponsor

Wake Forest University Health Sciences

Enrollment

46 participants

Start Date

Oct 4, 2024

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Pancreatic Cancer

Summary

The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Written informed consent and HIPAA authorization for release of personal health information
Patients pancreatic or invasive breast cancer per enrolling investigator who is planning on or has started anti-cancer treatment. Note: Patients with cancer who are not planning to receive anti-cancer treatment are not eligible for study participation
Patients with any severity of self-reported fatigue per enrolling investigator
Age ≥ 18 years at the time of consent
Ability to read and understand the English language
As determined by the enrolling investigator, the ability of the participant to understand and comply with study procedures (i.e., completing questionnaires and device return) for the entire length of the study

Exclusion Criteria4

Any documented, clinically significant cardiac-related abnormality per enrolling investigator that could compromise the outcome of the study. NOTE: The heart rate data collected using the WATD will not be used for patient care.
Other factors or conditions, per investigator discretion, for which participation in the study would not be in the patient's best interest or could interfere with study assessment results or preclude study completion
No internet, Wi-Fi access or email account
No access to a smartphone or mobile device